A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
for NASH With Fibrosis
Drug: Efruxifermin
205 locations incl. Birmingham
Sponsor: Akero Therapeutics, Inc
Sex: All·Age: 18 - 80
Code: NCT06215716·Phase 3·Recruiting